Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 + apatinib vs doxorubicin + ifosfamide in soft tissue sarcoma
CTR20181785Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in soft tissue sarcoma (STS), sponsored by Hengrui Therapeutics. Started Oct 2018; status: terminated.
02
Drugs
camrelizumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on CTR20181785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181785.